Fast itch relief and comparable skin clearance at week 4 - a nonsteroidal option to note for mild-moderate AD In a phase 2, dose‑ranging trial, twice‑daily 1.5% ruxolitinib cream matched…
Read More
A simple 1% colloidal oatmeal regimen cut itch and improved eczema scores within days in toddlers A small open‑label study in children aged 3-72 months tested a twice‑daily 1% colloidal…
Read More
A multi-acid, antioxidant delivery approach that promises boost in radiance and texture without PIH. Worth a look for patients with FST V–VI Facial rejuvenation that's both effective and safe in…
Read More
Honoring The Life of a Giant in Dermatologic Surgery We are all mourning the untimely passing of our esteemed colleague and friend, Dr Ron Moy, in July 2025. Dr Moy…
Read More
Acne Vulgaris... It pops up everywhere — in clinic, in conversation, and unfortunately, on our patients’ faces/trunks. While we’ve long leaned on prescription mainstays to zap zits, there’s a new family…
Read More
When One Target Isn’t Enough — Dual Therapy Clears Refractory ADW An adolescent with persistent, widespread atopic dermatitis failed topical therapy and dupilumab, then achieved only partial control on upadacitinib…
Read More
A Single‑Patient Signal That IL‑31 Blockade May Finally Tame The Relentless Itch Of Linear IgA Disease Linear IgA bullous dermatosis can be as much an itch disorder as a blistering…
Read More
Join JDD Podcast: Ask the Investigators as we celebrate almost a decade of dermatology insight with our trusted host, Dr. Adam Friedman. If you love learning with a smile, National…
Read More
Chatbots in the Waiting Room: How Reliable Are They for Dermatology Patients? Four consumer chatbots (ChatGPT 4o mini, Microsoft Copilot, Google Gemini Flash 1.5, and Perplexity) were asked about 25…
Read More
Psoriatic Arthritis Awareness Day: Reddit Sentiment Meets a Crohn’s Conundrum On September 28, Psoriatic Arthritis Awareness Day invites dermatologists to look beyond the clinic and into the digital communities where patients…
Read More
Clascoterone Keeps Gaining Ground in Acne Two identical Phase 3 trials (plus a long‑term extension) randomized patients ≥12 years with moderate‑to‑severe acne to twice‑daily clascoterone 1% cream or vehicle for…
Read More
Small Channels, Smarter Delivery - A Practical Boost For Topical And Regenerative Approaches Microneedling is proving to be a low‑risk, clinic-friendly way to enhance topical therapies (most consistently 5% minoxidil, now…
Read More
